Skip to search formSkip to main contentSkip to account menu

dexniguldipine

Known as: DNIG 
Dexniguldipine is the (+)-enantiomer of the dihydropyridine derivate niguldipine. Dexniguldipine showed a binding affinity to the P-glycoprotein and… 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

Dexniguldipine Hydrochloride
dexamethasone/dexniguldipine/doxorubicin/vincristine

Broader (1)

niguldipine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Inflammatory myofibroblastic lung tumor transforming into intracranial desmoplastic noninfantile ganglioglioma
Rationale: Inflammatory myofibroblastic tumor (IMT) of the lung often arises from excessive inflammatory response. It is one of… 
2004
2004
Tolerance, safety, and kinetics of the new antineoplastic compound dexniguldipine-HCl after oral administration: a phase I dose-escalation trial
Dexniguldipine-HCl is a new dihydropyridine compound that exerts selective antiproliferative activity in a variety of tumor… 
2003
2003
On the Paired Variants of TZ'AK
Students of Maya glyphs have long known of several unusual and imaginative forms of the logogram TZ’AK (“whole, complete”) where… 
2000
2000
In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia
Abstract Recent results show that the intracellular uptake pattern of idarubicin (IDA) in multidrug-resistant (MDR) cells is… 
1999
1999
PSC833, cyclosporin A, and dexniguldipine effects on cellular calcein retention and inhibition of the multidrug resistance pump in human leukemic lymphoblasts.
A convenient functional assay of the multidrug resistance (MDR) pump is useful for the diagnosis of MDR-1 cancers and the… 
1997
1997
Phase I and pharmacokinetic study of the P-glycoprotein modulator dexniguldipine-HCL.
Dexniguldipine (DNIG) is the R-enantiomer of the dihydropyridine derivate niguldipine. DNIG showed a binding affinity to the P… 
1996
1996
Rhodamine 123-efflux from hematopoietic subpopulations and leukaemic blast populations marked by PerCP-conjugated monoclonal antibodies.
1996
1996
In vivo reversibility of multidrug resistance by the MDR-modulator dexniguldipine (niguldipine derivative B859-35) and by verapamil.
The newly synthesized dihydropyridine derivative B859-35 was previously shown in vitro to be highly effective in reversing… 
1996
1996
P-glycoprotein-associated resistance to taxol and taxotere and its reversal by dexniguldipine-HCl, dexverapamil-HCl, or cyclosporin A.
A series of different human MDR (multidrug-resistant) cell lines including a HeLa-MDR1 transfectant which exhibit high… 
1992
1992
MDR hamster cells exhibiting multiple altered gene expression: effects of dexniguldipine-HCl (B859-35), cyclosporin A and buthionine sulfoximine.
An actinomycin D selected, multidrug-resistant (MDR) hamster CHO subline showed strong expression of the P-glycoprotein and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)